1887

Abstract

The mortality of clinical infections necessitates consideration of the utility of a vaccine. We have found that species can act as a protective vaccine against a lethal systemic infection, and describe experiments optimizing a subcutaneous regimen with killed yeast. Three injections of 2.5 mg given a week apart, 2 weeks prior to challenge, consistently, significantly, provided survival protection and reduction of infection in organs in survivors. The protection was independent of the strain of , and possibly even the species, and could be demonstrated in several inbred (including C′-deficient) and outbred mouse strains. The protective moiety(ies) appeared to reside in the cell wall and was resistant to 100 °C, but not to protease or formalin. Alum potentiated the protection. The protection was comparable or superior to that of several -specific preparations described in the literature. Other studies have indicated that heat-killed can protect against infection with at least three other fungal genera, raising the possibility of development of a panfungal vaccine, and such a vehicle has been studied in clinical trials, without dose-limiting toxicity.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.033290-0
2011-10-01
2020-08-05
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/10/1423.html?itemId=/content/journal/jmm/10.1099/jmm.0.033290-0&mimeType=html&fmt=ahah

References

  1. Bernard M., Latgé J. P. 2001; Aspergillus fumigatus cell wall: composition and biosynthesis. Med Mycol 39:Suppl. 19–17[PubMed] [CrossRef]
    [Google Scholar]
  2. Bernstein M. B., Chakraborty M., Wansley E. K., Guo Z., Franzusoff A., Mostböck S., Sabzevari H., Schlom J., Hodge J. W. 2008; Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 26:509–521 [CrossRef][PubMed]
    [Google Scholar]
  3. Bozza S., Clavaud C., Giovannini G., Fontaine T., Beauvais A., Sarfati J., D’Angelo C., Perruccio K., Bonifazi P. et al. 2009; Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol 183:2407–2414 [CrossRef][PubMed]
    [Google Scholar]
  4. Capilla J., Clemons K, Miller T. K., Selitrennikoff C., Stevens D. 2006; Aspergillus fumigatus antigens and fungal elements as vaccines against aspergillosis in mice. In 46th Interscience Conference on Antimicrobial Agents and ChemotherapySan FranciscoSeptember, 2006 abstract no. G-153 Washington, DC: American Society for Microbiology;
    [Google Scholar]
  5. Capilla J., Clemons K. V., Liu M., Levine H. B., Stevens D. A. 2009; Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine 27:3662–3668 [CrossRef][PubMed]
    [Google Scholar]
  6. Capilla Luque J. C., Clemons K. V., Stevens D. A. 2003; Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 47:1452–1455 [CrossRef][PubMed]
    [Google Scholar]
  7. Cenci E., Mencacci A., Bacci A., Bistoni F., Kurup V. P., Romani L. 2000; T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 165:381–388[PubMed] [CrossRef]
    [Google Scholar]
  8. Clemons K. V., Stevens D. A. 2004; Comparative efficacies of four amphotericin B formulations – Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet – against systemic murine aspergillosis. Antimicrob Agents Chemother 48:1047–1050 [CrossRef][PubMed]
    [Google Scholar]
  9. Clemons K. V., Stevens D. A. 2005; The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med Mycol 43:Suppl. 1S101–S110 [CrossRef][PubMed]
    [Google Scholar]
  10. Clemons K. V., Stevens D. A. 2009; Conventional or molecular measurement of Aspergillus load. Med Mycol 47:Suppl. 1S132–S137 [CrossRef][PubMed]
    [Google Scholar]
  11. Clemons K. V., McCusker J. H., Davis R. W., Stevens D. A. 1994; Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae . J Infect Dis 169:859–867 [CrossRef][PubMed]
    [Google Scholar]
  12. Clemons K. V., Park P., McCusker J. H., McCullough M. J., Davis R. W., Stevens D. A. 1997; Application of DNA typing methods and genetic analysis to epidemiology and taxonomy of Saccharomyces isolates. J Clin Microbiol 35:1822–1828[PubMed]
    [Google Scholar]
  13. Clemons K. V., Grunig G., Sobel R. A., Mirels L. F., Rennick D. M., Stevens D. A. 2000; Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis. Clin Exp Immunol 122:186–191 [CrossRef][PubMed]
    [Google Scholar]
  14. Clemons K. V., Miller T. K., Selitrennikoff C. P., Stevens D. A. 2002; fos-1, a putative histidine kinase as a virulence factor for systemic aspergillosis. Med Mycol 40:259–262[PubMed]
    [Google Scholar]
  15. Denning D. W., Stevens D. A. 1991; Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 35:1329–1333[PubMed] [CrossRef]
    [Google Scholar]
  16. Fierer J., Waters C., Walls L. 2006; Both CD4+ and CD8+ T cells can mediate vaccine-induced protection against Coccidioides immitis infection in mice. J Infect Dis 193:1323–1331 [CrossRef][PubMed]
    [Google Scholar]
  17. Finn A. 2004; Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 70:1–14 [CrossRef][PubMed]
    [Google Scholar]
  18. Franzusoff A., Duke R. C., King T. H., Lu Y., Rodell T. C. 2005; Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther 5:565–575 [CrossRef][PubMed]
    [Google Scholar]
  19. Goldblatt D. 2000; Conjugate vaccines. Clin Exp Immunol 119:1–3 [CrossRef][PubMed]
    [Google Scholar]
  20. Hanson L. H., Clemons K. V., Denning D. W., Stevens D. A. 1995; Efficacy of oral saperconazole in systemic murine aspergillosis. J Med Vet Mycol 33:311–317 [CrossRef][PubMed]
    [Google Scholar]
  21. Hearn V. M., Escott G. M., Evans E. G. V., Adams D. J. 1998; Complex chitinolytic system of Aspergillus fumigatus . Microbios 93:85–104[PubMed]
    [Google Scholar]
  22. Hector R. F., Yee E., Collins M. S. 1990; Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis. Infect Immun 58:1476–1478[PubMed]
    [Google Scholar]
  23. Heintel T., Breinig F., Schmitt M. J., Meyerhans A. 2003; Extensive MHC class I-restricted CD8 T lymphocyte responses against various yeast genera in humans. FEMS Immunol Med Microbiol 39:279–286 [CrossRef][PubMed]
    [Google Scholar]
  24. HogenEsch H. 2002; Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20:Suppl. 3S34–S39 [CrossRef][PubMed]
    [Google Scholar]
  25. Hunter R. L. 2002; Overview of vaccine adjuvants: present and future. Vaccine 20:Suppl. 3S7–S12 [CrossRef][PubMed]
    [Google Scholar]
  26. Ito J. I., Lyons J. M., Hong T. B., Tamae D., Liu Y. K., Wilczynski S. P., Kalkum M. 2006; Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun 74:5075–5084 [CrossRef][PubMed]
    [Google Scholar]
  27. Klis F. M., Mol P., Hellingwerf K., Brul S. 2002; Dynamics of cell wall structure in Saccharomyces cerevisiae . FEMS Microbiol Rev 26:239–256 [CrossRef][PubMed]
    [Google Scholar]
  28. Kuranda M. J., Robbins P. W. 1991; Chitinase is required for cell separation during growth of Saccharomyces cerevisiae . J Biol Chem 266:19758–19767[PubMed]
    [Google Scholar]
  29. Kurup V. P., Ramasamy M., Greenberger P. A., Fink J. N. 1988; Isolation and characterization of a relevant Aspergillus fumigatus antigen with IgG- and IgE-binding activity. Int Arch Allergy Appl Immunol 86:176–182 [CrossRef][PubMed]
    [Google Scholar]
  30. Lachin J. M. 1999; Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials 20:408–422 [CrossRef][PubMed]
    [Google Scholar]
  31. Lees A., Nelson B. L., Mond J. J. 1996; Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14:190–198 [CrossRef][PubMed]
    [Google Scholar]
  32. Levine H. B., Pappagianis D., Cobb J. M. 1970; Development of vaccines for coccidioidomycosis. Mycopathol Mycol Appl 41:177–185 [CrossRef][PubMed]
    [Google Scholar]
  33. Lin S. J., Schranz J., Teutsch S. M. 2001; Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32:358–366 [CrossRef][PubMed]
    [Google Scholar]
  34. Liu M., Machova E., Nescakova Z., Clemons K., Martinez M., Chen V., Bystricky S., Stevens D. A. 2009; Vaccination with mannan protects mice against invasive aspergillosis. In 49th Interscience Conference on Antimicrobial Agents and ChemotherapySan FranciscoSeptember, 2009 abstract no. G1-892 Washington, DC: American Society for Microbiology;
    [Google Scholar]
  35. Liu M., Clemons K., Bystricky S., Stevens D. 2010a; Glycans and conjugates as vaccines against coccidioidomycosis. In 50th Interscience Conference on Antimicrobial Agents and ChemotherapyBostonSeptember, 2010 abstract no. G1-1657 Washington, DC: American Society for Microbiology;
    [Google Scholar]
  36. Liu M., Clemons K., Machova E., Medovarska I., Stevens D. 2010b; Effect of different molecular sizes of mannan as vaccines against invasive aspergillosis. In 50th Interscience Conference on Antimicrobial Agents and ChemotherapyBostonSeptember, 2010 abstract no. G1-1658 Washington, DC: American Society for Microbiology;
    [Google Scholar]
  37. Liu M., Clemons K., Johansen M., Martinez M., Chen V., Stevens D. 2010c; Saccharomyces as a vaccine against systemic candidiasis. In 50th Interscience Conference on Antimicrobial Agents and ChemotherapyBostonSeptember, 2010 abstract no. G1-1656 Washington, DC: American Society for Microbiology;
    [Google Scholar]
  38. Liu M., Clemons K. V., Bigos M., Medovarska I., Brummer E., Stevens D. A. 2011; Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine 29:1745–1753 [CrossRef][PubMed]
    [Google Scholar]
  39. Lu Y., Bellgrau D., Dwyer-Nield L. D., Malkinson A. M., Duke R. C., Rodell T. C., Franzusoff A. 2004; Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 64:5084–5088 [CrossRef][PubMed]
    [Google Scholar]
  40. Lucas A. H., Apicella M. A., Taylor C. E. 2005; Carbohydrate moieties as vaccine candidates. Clin Infect Dis 41:705–712 [CrossRef][PubMed]
    [Google Scholar]
  41. Majumder, T., Liu, M., Chen, V., Martinez, M., Alvarado, D., Clemons, K. V. & Stevens, D. A. (2011 Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii.. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September, 2011, abstract no. G1-769. Washington, DC: American Society for Microbiology
  42. Mortimer R. K., Johnston J. R. 1986; Genealogy of principal strains of the yeast genetic stock center. Genetics 113:35–43[PubMed]
    [Google Scholar]
  43. Munson S., Parker J., King T., Lu Y., Kelley V., Guo Z., Borges V., Franzusoff A. 2007; Coupling innate and adaptive immunity with yeast-based cancer immunotherapy. In Cancer Vaccines and Tumor Immunity pp. 131–149 Edited by Orentas R., Hodge J. W., Johnson B. D. Hoboken, NJ: John Wiley & Sons; [CrossRef]
    [Google Scholar]
  44. Pishko E. J., Kirkland T. N., Cole G. T. 1995; Isolation and characterization of two chitinase-encoding genes (cts1, cts2) from the fungus Coccidioides immitis . Gene 167:173–177 [CrossRef][PubMed]
    [Google Scholar]
  45. Richard J. L., Thurston J. R., Cutlip R. C., Pier A. C. 1982; Vaccination studies of aspergillosis in turkeys: subcutaneous inoculation with several vaccine preparations followed by aerosol challenge exposure. Am J Vet Res 43:488–492[PubMed]
    [Google Scholar]
  46. Salehen N., Stover C. 2008; The role of complement in the success of vaccination with conjugated vs. unconjugated polysaccharide antigen. Vaccine 26:451–459 [CrossRef][PubMed]
    [Google Scholar]
  47. Shih W. 2002; Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 3:4 [CrossRef][PubMed]
    [Google Scholar]
  48. Stevens D. A., Clemons K. V., Liu M. 2011; Developing a vaccine against aspergillosis. Med Mycol 49:Suppl. 1S170–S176 [CrossRef][PubMed]
    [Google Scholar]
  49. Stubbs A. C., Martin K. S., Coeshott C., Skaates S. V., Kuritzkes D. R., Bellgrau D., Franzusoff A., Duke R. C., Wilson C. C. 2001; Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7:625–629 [CrossRef][PubMed]
    [Google Scholar]
  50. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., Norelli F., Bellucci C., Polonelli L. et al. 2005; A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202:597–606 [CrossRef][PubMed]
    [Google Scholar]
  51. Walsh T. J., Anaissie E. J., Denning D. W., Herbrecht R., Kontoyiannis D. P., Marr K. A., Morrison V. A., Segal B. H., Steinbach W. J. et al. 2008; Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360 [CrossRef][PubMed]
    [Google Scholar]
  52. Weaver D. J. Jr, Reis E. S., Pandey M. K., Köhl G., Harris N., Gerard C., Köhl J. 2010; C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur J Immunol 40:710–721 [CrossRef][PubMed]
    [Google Scholar]
  53. Wightman R., Meacock P. A. 2003; The THI5 gene family of Saccharomyces cerevisiae: distribution of homologues among the hemiascomycetes and functional redundancy in the aerobic biosynthesis of thiamin from pyridoxine. Microbiology 149:1447–1460 [CrossRef][PubMed]
    [Google Scholar]
  54. Wuthrich M., Filutowicz H. I., Warner T., Deepe G. S. Jr, Klein B. S. 2003; Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med 197:1405–1416 [CrossRef][PubMed]
    [Google Scholar]
  55. Xue J., Chen X., Selby D., Hung C. Y., Yu J. J., Cole G. T. 2009; A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect Immun 77:3196–3208 [CrossRef][PubMed]
    [Google Scholar]
  56. Zheng M., Ramsay A. J., Robichaux M. B., Norris K. A., Kliment C., Crowe C., Rapaka R. R., Steele C., McAllister F. et al. 2005; CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest 115:3536–3544 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.033290-0
Loading
/content/journal/jmm/10.1099/jmm.0.033290-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error